Wednesday, June 21, 2023

8:00 Welcome & Introductions
Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:30 Respiratory Syncytial Virus Vaccines - Adult
Introduction
Dr. Camille Kotton (ACIP, WG Chair)
Manufacturer presentation: Pfizer season 2 safety & efficacy; coadministration with influenza vaccine
Dr. Alejandra Gurtman (Pfizer)
Manufacturer presentation: GSK season 2 safety & efficacy; coadministration with influenza vaccine
Dr. Leonard Friedland (GSK)
Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model)
Dr. David Hutton (University of Michigan)
Comparison of cost effectiveness results of the main CDC model and each manufacturer model (Pfizer & GSK)
Dr. Ismael Ortega Sanchez (CDC/NCIRD)
Updated Etr (incl. GRADE) and clinical considerations for 2 vaccines (Pfizer & GSK)
Dr. Michael Melgar (CDC/NCIRD)

11:45 Break

12:45 Polio Vaccine
Introduction
Dr. Oliver Brooks (ACIP, WG Chair)
Recommendations for Adult Polio Vaccination
Dr. Sarah Kidd (CDC/NCIRD)

2:15 Break

2:30 Influenza Vaccines
Introduction
Dr. H. Keipp Talbot (ACIP, WG Chair)
WG considerations and proposed recommendations
Dr. Lisa Grohskopf (CDC/NCIRD)

4:00 Break

4:15 Public Comment

4:35 VOTES
RSV Adult Vaccines
Dr. Michael Melgar (CDC/NCIRD)
Polio Vaccine
Dr. Sarah Kidd (CDC/NCIRD)
Influenza Vaccines
Dr. Lisa Grohskopf (CDC/NCIRD)

VFC VOTE
Influenza Vaccines
Dr. Jeanne Santoli (CDC/NCIRD)

5:30 Adjourn
Thursday, June 22, 2023

8:00 Welcome & Introductions
Dr. Grace Lee (ACIP Chair)
Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

8:35 Agency Updates
CDC, CMS, FDA, HRSA, IHS, OIDP, NIH

8:55 Pneumococcal Vaccines
Introduction
Dr. Kathy Poehling (ACIP, WG Chair)
Dr. Charles Stoecker (Tulane University)
Dr. Ayabina Diepreye (CDC/NCIRD)
Dr. Miwako Kobayashi (CDC/NCIRD)

8:55 Comparison of cost-effectiveness analyses on PCV20 use in children
Dr. Ayabina Diepreye (CDC/NCIRD)

8:55 Summary of WG interpretation on EtR and policy options
Dr. Miwako Kobayashi (CDC/NCIRD)

10:25 Break

10:40 Dengue Vaccines
Introduction
Dr. Wilbur Chen (ACIP, WG Chair)
Dr. Alfonso Hernandez (CDC/NCEZID)
Dr. Guido Espana (University of Notre Dame)
Dr. RajReni Kaul (CDC/NCIRD)
Dr. Joshua Wong (CDC/NCEZID)

10:40 Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico
Dr. Wilbur Chen (ACIP, WG Chair)
Dr. Alfonso Hernandez (CDC/NCEZID)

10:40 Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico
Dr. RajReni Kaul (CDC/NCIRD)

10:40 Partial EtR framework for TAK-003
Dr. Joshua Wong (CDC/NCEZID)

11:40 Break

12:25 Chikungunya Vaccine
Introduction
Dr. Beth Bell (ACIP, WG Chair)
Ms. Nicole Lindsey (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID)
Dr. Susan Hills (CDC/NCEZID)

12:25 Value of chikungunya vaccine to U.S. travelers and providers
Ms. Nicole Lindsey (CDC/NCEZID)

12:25 Chikungunya virus infection among laboratory workers
Dr. Susan Hills (CDC/NCEZID)

12:25 Update on large chikungunya outbreak in Paraguay
Dr. Susan Hills (CDC/NCEZID)

12:25 Workgroup plans and timelines
Dr. Susan Hills (CDC/NCEZID)

1:25 Break

1:40 Respiratory Syncytial Virus Vaccines - Pediatric/Maternal
Introduction
Dr. Sarah Long (ACIP, WG Chair)
Dr. David Hutton (University of Michigan)

1:40 Economic analysis of RSVpreF in pediatric populations
Dr. David Hutton (University of Michigan)

1:40 EtR Pfizer maternal RSV vaccine
Dr. Katherine Fleming-Dutra (CDC/NCIRD)

1:40 Economic analysis of combined use of nirsevimab and maternal RSVpreF vaccine
Dr. David Hutton (University of Michigan)

1:40 Clinical considerations for RSV maternal vaccine and nirsevimab
Dr. Jefferson Jones (CDC, NCIRD)

4:40 Break

4:50 Public Comment

5:10 VOTES
Pneumococcal vaccines
Dr. Jeanne Santoli (CDC/NCIRD)

VFC VOTE
Pneumococcal Vaccines
Dr. Jeanne Santoli (CDC/NCIRD)

5:30 Adjorn
### Friday, June 23, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome &amp; Introductions</td>
<td>Dr. Grace Lee (ACIP Chair)</td>
</tr>
<tr>
<td>8:10</td>
<td>Mpox Vaccine</td>
<td>Dr. Pablo Sanchez (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>Dr. Faisal Minhaj (CDC/NCEZID)</td>
</tr>
<tr>
<td></td>
<td>Updates From the 2022/2023 U.S. Mpox Outbreak: Epidemiology, Vaccine Safety, and Vaccine Effectiveness</td>
<td>Dr. Agam Rao (CDC/NCEZID)</td>
</tr>
<tr>
<td></td>
<td>Use of JYNNEOS During Mpox Outbreaks: Clinical guidance</td>
<td>Dr. Agam Rao (CDC/NCEZID)</td>
</tr>
<tr>
<td>10:10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>Meningococcal Vaccines</td>
<td>Dr. Kathy Poehling (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>Dr. Ismael Ortega-Sanchez (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>Cost effectiveness analysis</td>
<td>Dr. Sam Crowe (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>GRADE/EtR</td>
<td>Dr. Sam Crowe (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>Summary and workgroup considerations</td>
<td>Dr. Sam Crowe (CDC/NCIRD)</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td>Vaccine Safety</td>
<td>Dr. Matthew Daley (Kaiser Permanente Colorado)</td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td>Dr. Anders Hviid (Statens Serum Institut, Copenhagen, Denmark)</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:40</td>
<td>COVID-19 Vaccines</td>
<td>Dr. Matthew Daley (ACIP WG Chair)</td>
</tr>
<tr>
<td></td>
<td>Introduction</td>
<td>Dr. Fiona Havers (CDC/NCIRD), Dr. Romeo Galang (CDC/NCCDPHP), Dr. Ruth Link-Gelles (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>Updates to COVID-19 epidemiology and vaccine effectiveness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Infection-induced and hybrid immunity</td>
<td>Dr. Jefferson Jones (CDC/NCIRD)</td>
</tr>
<tr>
<td></td>
<td>Summary and work group considerations</td>
<td>Dr. Megan Wallace (CDC/NCIRD)</td>
</tr>
<tr>
<td>2:40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Acronyms

- **CDC**: Centers for Disease Control and Prevention
- **CMS**: Centers for Medicare and Medicaid Services
- **COVID-19**: Coronavirus disease 2019
- **EtR**: Evidence to Recommendations Framework
- **FDA**: Food and Drug Administration
- **GRADE**: Grading of Recommendations Assessment, Development and Evaluation
- **HRSA**: Health Resources and Services Administration
- **IHS**: Indian Health Service
- **NCHHSTP**: National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
- **NCIRD**: National Center for Immunization & Respiratory Diseases [of CDC/OID]
- **NCEZID**: National Center for Emerging and Zoonotic Diseases [of CDC/OID]
- **NIAID**: National Institute of Allergy and Infectious Diseases
- **OIDP**: Office of Infectious Disease and HIV/AIDS Policy
- **SARS-CoV-2**: Severe Acute Respiratory Syndrome Coronavirus 2
- **WG**: Work Group
- **WHO**: World Health Organization
- **VE**: Vaccine Effectiveness